0001654954-22-000280.txt : 20220106 0001654954-22-000280.hdr.sgml : 20220106 20220106163849 ACCESSION NUMBER: 0001654954-22-000280 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220106 DATE AS OF CHANGE: 20220106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AEHR TEST SYSTEMS CENTRAL INDEX KEY: 0001040470 STANDARD INDUSTRIAL CLASSIFICATION: INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & ELEC SIGNALS [3825] IRS NUMBER: 942424084 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22893 FILM NUMBER: 22515250 BUSINESS ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 BUSINESS PHONE: 5106239400 MAIL ADDRESS: STREET 1: 400 KATO TERRACE CITY: FREMONT STATE: CA ZIP: 94539 8-K 1 aehr_8k.htm FORM 8-K aehr_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

 January 6, 2022

  

AEHR TEST SYSTEMS

(Exact name of registrant as specified in its charter)

  

California

 

000-22893

 

94-2424084

(State or other jurisdiction
of incorporation)

 

(Commission

File Number)

 

(IRS Employer
Identification No.)

 

400 KATO TERRACE
FREMONT, CA 94539

(Address of principal executive offices, including zip code)

 

510-623-9400

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.01 per share

AEHR

The NASDAQ Capital Market

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On January 6, 2022, Aehr Test Systems, or the Company, issued a press release announcing the Company’s financial results for its second quarter of fiscal year 2022 ended November 30, 2021. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K, including the exhibit attached hereto, are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release of Aehr Test Systems dated January 6, 2022 entitled “Aehr Test Reports Second Consecutive Quarter of Record Bookings in Second Quarter of Fiscal 2022 on Strength of Semiconductor Test and Burn-In Sales for Electric Vehicles.”

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   

 

Aehr Test Systems

(Registrant)

    
Date: January 6, 2022 By:/s/ Kenneth B. Spink

 

 

Kenneth B. Spink 
  Vice President of Finance and 
  

Chief Financial Officer

 

 

 

3

 

EX-99.1 2 aehr_ex991.htm ADDITIONAL EXHIBITS aehr_ex991.htm

EXHIBIT 99.1

 

 

FOR IMMEDIATE RELEASE

 

Contacts:

 

 

 

Aehr Test Systems

MKR Investor Relations Inc.

Ken Spink

Todd Kehrli or Jim Byers

Chief Financial Officer

Analyst/Investor Contact

(510) 623-9400 x309

(323) 468-2300

 

aehr@mkr-group.com

  

Aehr Test Reports Second Consecutive Quarter of Record Bookings in Second Quarter of

Fiscal 2022 on Strength of Semiconductor Test and Burn-In Sales for Electric Vehicles

 

Fremont, CA (January 6, 2022) – Aehr Test Systems (NASDAQ: AEHR), a worldwide supplier of semiconductor test and reliability qualification equipment, today announced financial results for its second quarter of fiscal 2022 ended November 30, 2021.

 

Fiscal Second Quarter Financial Results:

 

 

·

Net sales were $9.6 million, up 471% from $1.7 million in the second quarter of fiscal 2021.

 

·

GAAP net income was $717,000, or $0.03 per diluted share, compared to a GAAP net loss of $2.0 million, or $0.08 per diluted share, in the second quarter of fiscal 2021.

 

·

Non-GAAP net income was $1.4 million, or $0.05 per diluted share, which excludes the impact of stock-based compensation, compared to a non-GAAP net loss of $1.7 million, or $0.07 per diluted share, in the second quarter of fiscal 2021.

 

·

Bookings were $29.1 million for the quarter ended November 30, 2021, the Company’s quarterly highest bookings on record, compared to $1.6 million in the second quarter of fiscal 2021.

 

·

Backlog as of November 30, 2021 was $36.1 million, the Company’s highest backlog on record.

 

Fiscal First Six Months Financial Results:

 

 

·

Net sales were $15.3 million, up 313% from $3.7 million in the first six months of fiscal 2021.

 

·

GAAP net income was $1.4 million, or $0.05 per diluted share, which includes the impact of forgiveness of $1.7 million in loans from the Paycheck Protection Program (“PPP”) received in fiscal 2020. This compares to a GAAP net loss of $1.9 million, or $0.08 per diluted share, in the first six months of fiscal 2021, which includes the impact of stock-based compensation and a non-cash net gain of $2.2 million and tax benefit of $215,000 related to the closure of Aehr’s Japan subsidiary during the first quarter of fiscal 2021.

 

·

Non-GAAP net income was $1.0 million, or $0.04 per diluted share, which excludes the impact of stock-based compensation and forgiveness of the PPP loan. This compares to a non-GAAP net loss of $3.7 million, or $0.16 per diluted share, in the first six months of fiscal 2021, which excludes the impact of stock-based compensation and the net gain related to the closure of Aehr’s Japan subsidiary during the first quarter of fiscal 2021.

 

An explanation of the use of non-GAAP financial measures and a reconciliation of Aehr’s non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying tables.

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2022 Financial Results

January 6, 2022

Page 2 of 7 

 

Gayn Erickson, President and CEO of Aehr Test Systems, commented:

 

“We finished the second quarter with record bookings for a single quarter of $29.1 million and our highest backlog on record of $36.1 million. Including the announced orders since the beginning of the fiscal third quarter, our total bookings for the fiscal year to date is over $52 million.

 

“We continue to see very strong interest and demand for wafer level test and burn-in of silicon carbide devices, particularly for use directly in, and in support of, the electric vehicle market. We are ramping our FOXTM multi-wafer test and burn-in systems and full wafer WaferPakTM capacity to meet this upcoming silicon carbide market opportunity, which we believe will grow significantly over the next decade or more. We are only at the very beginning of this ramp as electric vehicles accounted for a very small percentage share of the overall market last year and are expected to be over 30% of total vehicles sold by 2030.

 

“During the quarter we received a $19.4 million order for our FOX-XPTM wafer level test and burn-in systems from our lead silicon carbide customer. This order was then followed by a $7.6 million order for WaferPaks that do not fully populate the systems, so we are expecting additional follow on WaferPak orders for these production FOX-XP systems. These systems and WaferPaks are being used to test and burn-in MOSFET devices in traction inverters in electric vehicle motor controllers, as well as both on-board and off-board electric vehicle chargers. This customer, a major automotive semiconductor supplier with a significant customer base in the automotive semiconductor market, continues to forecast significant additional system and WaferPak purchases over the next several years. Multiple industry forecasters and analysts expect the market for silicon carbide devices to grow at a compound annual growth rate (CAGR) of more than 30% over the next decade driven by demand from the electric vehicle market and other applications.

 

“In addition to a very strong backlog and forecast from our lead silicon carbide customer, we are currently engaged in discussions and/or evaluations with several other silicon carbide suppliers regarding their wafer level test and burn-in needs. This includes at least one large silicon carbide supplier that has moved to on-wafer evaluation and benchmarking of Aehr’s FOX-XP multi-wafer system for testing and burning in their silicon carbide wafers. We believe we will add several new silicon carbide customers that will ramp into production by next fiscal year on our solutions.

 

“Another positive is that we continue to see signs of strengthening in the silicon photonics test and burn-in market as our FOX multi-wafer systems and WaferPaks provide a very cost effective and scalable solution for “burning in” the optical lasers and stabilizing their output power while also removing any extrinsic or early life failures. In addition to the silicon photonics devices that are now ramping into production for fiberoptic transceivers for datacom and telecom applications such as data center and 5G infrastructure, several companies have made public announcements of their intent to integrate silicon photonics devices and co-packaged optics in high end processor applications and intra-chip as well as inter-chip communications within the next few years.

 

“During the last few months, we received orders from a current silicon photonics customer for six additional FOX-NP™ systems to support the characterization and product qualification of new types of photonics-based devices. This customer is expected to purchase new sets of WaferPaks to be used with these systems. As the applications and market for silicon photonics-based devices continue to grow, we expect this customer to continue to increase their capacity in the future.

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2022 Financial Results

January 6, 2022

Page 3 of 7

 

“Several other customers addressing the silicon photonics market have also forecast additional FOX system and WaferPak or DiePak® contactor capacity needs over the next 12 months. These include needs to address incremental production capacity as well as capacity to address new customer and new product qualification and engineering. Silicon photonics devices address the 5G and data center infrastructure industry as well as several other key markets today, and Yole Research predicts that the silicon photonics transceiver market alone will reach $4.6 billion in 2026, with a CAGR of 25% between 2021 and 2026.

 

“We remain very focused on serving the very large market opportunities we see ahead, which include the significant opportunity for test and burn-in of silicon carbide devices for electric vehicles and electrification infrastructure, silicon photonics devices for data center and 5G infrastructure, and 2D/3D sensors for mobile and wearable devices. With our record bookings and the strength of our semiconductor test and burn-in solutions, we are confident in our ability to deliver significant revenue growth and are reiterating our guidance for revenue for the year.”

 

Fiscal 2022 Financial Guidance:

 

For the fiscal year ending May 31, 2022, Aehr is reiterating its previously provided guidance for full year total revenue of at least $50 million, and to be profitable for the fiscal year at these revenue levels based upon its operating model.

 

Management Conference Call and Webcast

 

Aehr Test Systems will host a conference call and webcast today at 5:00 p.m. Eastern (2:00 p.m. PT) to discuss its fiscal 2022 second quarter operating results. To access the live call, dial 800-437-2398 (US and Canada) or +1 929-477-0577 (International) and give the participant passcode 5907605. In addition, a live and archived webcast of the conference call will be available over the Internet at www.aehr.com in the Investor Relations section and at the following link https://edge.media-server.com/mmc/p/ewc7mhgg. A replay of the conference call will also be available via telephone beginning approximately two hours after conclusion of the call through 8:00 p.m. ET on January 13, 2022. To access the replay dial-in information, please click here.

 

About Aehr Test Systems

 

Headquartered in Fremont, California, Aehr Test Systems is a worldwide provider of test systems for burning-in and testing logic, optical and memory integrated circuits and has installed over 2,500 systems worldwide. Increased quality and reliability needs of the Automotive and Mobility integrated circuit markets are driving additional test requirements, incremental capacity needs, and new opportunities for Aehr Test products in package, wafer level, and singulated die/module level test. Aehr Test has developed and introduced several innovative products, including the ABTSTM and FOX-PTM families of test and burn-in systems and FOX WaferPakTM Aligner, FOX-XP WaferPak Contactor, FOX DiePak® Carrier and FOX DiePak Loader. The ABTS system is used in production and qualification testing of packaged parts for both lower power and higher power logic devices as well as all common types of memory devices. The FOX-XP and FOX-NP systems are full wafer contact and singulated die/module test and burn-in systems used for burn-in and functional test of complex devices, such as leading-edge memories, digital signal processors, microprocessors, microcontrollers, systems-on-a-chip, and integrated optical devices. The FOX-CP system is a new low-cost single-wafer compact test and reliability verification solution for logic, memory and photonic devices and the newest addition to the FOX-P product family. The WaferPak Contactor contains a unique full wafer probe card capable of testing wafers up to 300mm that enables IC manufacturers to perform test and burn-in of full wafers on Aehr Test FOX systems. The DiePak Carrier is a reusable, temporary package that enables IC manufacturers to perform cost-effective final test and burn-in of both bare die and modules. For more information, please visit Aehr Test Systems’ website at www.aehr.com.

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2022 Financial Results

January 6, 2022

Page 4 of 7

 

Safe Harbor Statement


This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally relate to future events or Aehr’s future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “going to,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “sees,” or “continue,” or the negative of these words or other similar terms or expressions that concern Aehr’s expectations, strategy, priorities, plans, or intentions. Forward-looking statements in this press release include, but are not limited to, Aehr’s ability to generate bookings and revenue increases in the future, including the first quarter of fiscal 2022; future requirements and orders of Aehr’s new and existing customers; bookings forecasted for proprietary WaferPakTM and DiePak consumables across multiple market segments; the temporary nature of customer pushouts; shipping timelines for products and follow-on capacity orders; the growth of Aehr’s systems and consumables, including as a percentage of total sales; financial guidance for fiscal 2022, including related to revenue and profitability, and expectations regarding fiscal 2022; Aehr’s ability to expand its number of customers using its FOX-PTM solutions; the ability to secure potential customer engagements; expectations related to long-term demand for Aehr’s productions and the attractiveness of key markets; the belief that Aehr will be stronger after the current worldwide COVID-19 pandemic, including expectations related to greater production, more customers, more applications, and higher value products. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in Aehr’s recent 10-K, 10-Q and other reports filed from time to time with the Securities and Exchange Commission. Aehr disclaims any obligation to update information contained in any forward-looking statement to reflect events or circumstances occurring after the date of this press release.

 

– Financial Tables to Follow –

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2022 Financial Results

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

January 6, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Page 5 of 7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

Nov 30,

 

 

Aug 31,

 

 

Nov 30,

 

 

Nov 30,

 

 

Nov 30,

 

 

 

2021

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$ 9,611

 

 

$ 5,646

 

 

$ 1,683

 

 

$ 15,257

 

 

$ 3,695

 

Cost of sales

 

 

5,092

 

 

 

3,365

 

 

 

1,306

 

 

 

8,457

 

 

 

3,091

 

Gross profit

 

 

4,519

 

 

 

2,281

 

 

 

377

 

 

 

6,800

 

 

 

604

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

2,489

 

 

 

1,953

 

 

 

1,501

 

 

 

4,442

 

 

 

3,015

 

Research and development

 

 

1,313

 

 

 

1,321

 

 

 

820

 

 

 

2,634

 

 

 

1,720

 

Total operating expenses

 

 

3,802

 

 

 

3,274

 

 

 

2,321

 

 

 

7,076

 

 

 

4,735

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) from operations

 

 

717

 

 

 

(993 )

 

 

(1,944 )

 

 

(276 )

 

 

(4,131 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(1 )

 

 

(9 )

 

 

(12 )

 

 

(10 )

 

 

(25 )

Income from forgiveness of PPP loan

 

 

-

 

 

 

1,698

 

 

 

-

 

 

 

1,698

 

 

 

-

 

Net gain from dissolution of Aehr Test Systems Japan

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,186

 

Other income (expense), net

 

 

35

 

 

 

23

 

 

 

(6 )

 

 

58

 

 

 

(100 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before income tax (expense) benefit

 

 

751

 

 

 

719

 

 

 

(1,962 )

 

 

1,470

 

 

 

(2,070 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax (expense) benefit

 

 

(34 )

 

 

(23 )

 

 

(4 )

 

 

(57 )

 

 

211

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$ 717

 

 

$ 696

 

 

$ (1,966 )

 

$ 1,413

 

 

$ (1,859 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$ 0.03

 

 

$ 0.03

 

 

$ (0.08 )

 

$ 0.06

 

 

$ (0.08 )

Diluted

 

$ 0.03

 

 

$ 0.03

 

 

$ (0.08 )

 

$ 0.05

 

 

$ (0.08 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in per share calculations:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

26,205

 

 

 

23,999

 

 

 

23,396

 

 

 

25,102

 

 

 

23,322

 

Diluted

 

 

28,342

 

 

 

25,356

 

 

 

23,396

 

 

 

26,849

 

 

 

23,322

 

 

-more-

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2022 Financial Results

 

 

 

 

 

 

 

 

 

 

January 6, 2022

 

 

 

 

 

 

 

 

 

 

Page 6 of 7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

Reconciliation of GAAP and Non-GAAP Results

(in thousands, except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

Nov 30,

 

 

Aug 31,

 

 

Nov 30,

 

 

Nov 30,

 

 

Nov 30,

 

 

 

2021

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss)

 

$ 717

 

 

$ 696

 

 

$ (1,966 )

 

$ 1,413

 

 

$ (1,859 )

Stock-based compensation expense

 

 

718

 

 

 

588

 

 

 

257

 

 

 

1,306

 

 

 

527

 

Income from forgiveness of PPP loan

 

 

-

 

 

 

(1,698 )

 

 

-

 

 

 

(1,698 )

 

 

-

 

Income from disolution of Aehr Test Systesm Japan

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,401 )

Non-GAAP net income (loss)

 

$ 1,435

 

 

$ (414 )

 

$ (1,709 )

 

$ 1,021

 

 

$ (3,733 )

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss) per diluted share

 

$ 0.03

 

 

$ 0.03

 

 

$ (0.08 )

 

$ 0.05

 

 

$ (0.08 )

Non-GAAP net income (loss) per diluted share

 

$ 0.05

 

 

$ (0.02 )

 

$ (0.07 )

 

$ 0.04

 

 

$ (0.16 )

Shares used in GAAP diluted shares calculation

 

 

28,342

 

 

 

25,356

 

 

 

23,396

 

 

 

26,849

 

 

 

23,322

 

Shares used in non-GAAP diluted shares calculation

 

 

28,342

 

 

 

23,999

 

 

 

23,396

 

 

 

26,849

 

 

 

23,322

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income (loss) is a non-GAAP measure and should not be considered a replacement for GAAP results. Non-GAAP net income (loss) is a financial measure the Company uses to evaluate the underlying results and operating performance of the business. The limitation of this measure is that it excludes items that impact the Company's current period net income. This limitation is best addressed by using this measure in combination with net income (loss) (the most directly comparable GAAP financial measure). These measures are not in accordance with GAAP and may differ from non-GAAP methods of accounting and reporting used by other companies.
 
We believe these measures enhance investors’ ability to review the company’s business from the same perspective as the Company’s management and facilitate comparisons of this period’s results with prior periods.

 

-more-

 

 

 

 

Aehr Test Systems Reports Second Quarter Fiscal 2022 Financial Results

 

 

 

 

 

 

January 6, 2022

 

 

 

 

 

 

Page 7 of 7

 

 

 

 

 

 

 

 

 

 

 

 

 

AEHR TEST SYSTEMS AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

(unaudited)

 

 

 

 

 

 

 

 

 

November 30,

 

 

August 31,

 

 

May 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$ 35,031

 

 

$ 6,530

 

 

$ 4,582

 

Accounts receivable, net

 

 

7,391

 

 

 

4,264

 

 

 

5,202

 

Inventories

 

 

13,033

 

 

 

10,146

 

 

 

8,849

 

Prepaid expenses and other

 

 

622

 

 

 

759

 

 

 

551

 

Total current assets

 

 

56,077

 

 

 

21,699

 

 

 

19,184

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

661

 

 

 

676

 

 

 

677

 

Operating lease right-of-use assets

 

 

1,265

 

 

 

1,437

 

 

 

1,606

 

Other assets

 

 

182

 

 

 

189

 

 

 

198

 

Total assets

 

$ 58,185

 

 

$ 24,001

 

 

$ 21,665

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$ 3,386

 

 

$ 2,753

 

 

$ 2,893

 

Accrued expenses

 

 

2,254

 

 

 

1,978

 

 

 

2,163

 

Operating lease liabilities, short-term

 

 

763

 

 

 

750

 

 

 

737

 

Customer deposits and deferred revenue, short-term

 

 

10,142

 

 

 

3,279

 

 

 

189

 

Line of credit

 

 

-

 

 

 

-

 

 

 

1,400

 

Current portion of long-term debt

 

 

-

 

 

 

-

 

 

 

1,679

 

Total current liabilities

 

 

16,545

 

 

 

8,760

 

 

 

9,061

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating lease liabilities, long-term

 

 

616

 

 

 

813

 

 

 

1,007

 

Long-term debt, net of current portion

 

 

-

 

 

 

-

 

 

 

-

 

Deferred revenue, long-term

 

 

116

 

 

 

150

 

 

 

99

 

Other liabilities

 

 

46

 

 

 

46

 

 

 

49

 

Total liabilities

 

 

17,323

 

 

 

9,769

 

 

 

10,216

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total shareholders' equity

 

 

40,862

 

 

 

14,232

 

 

 

11,449

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total liabilities and shareholders' equity

 

$ 58,185

 

 

$ 24,001

 

 

$ 21,665

 

 

 

# # #

 

GRAPHIC 3 aehr_ex991img2.jpg IMAGE begin 644 aehr_ex991img2.jpg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�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end EX-101.SCH 4 aehr-20220106.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 aehr-20220106_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 aehr-20220106_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 aehr-20220106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Incorporation State Country Code Entity File Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Trading Symbol Security Exchange Name EX-101.PRE 8 aehr-20220106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Jan. 06, 2022
Cover [Abstract]  
Entity Registrant Name AEHR TEST SYSTEMS
Entity Central Index Key 0001040470
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jan. 06, 2022
Entity Incorporation State Country Code CA
Entity File Number 000-22893
Entity Tax Identification Number 94-2424084
Entity Address Address Line 1 400 KATO TERRACE
Entity Address City Or Town FREMONT
Entity Address State Or Province CA
Entity Address Postal Zip Code 94539
City Area Code 510
Local Phone Number 623-9400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol AEHR
Security Exchange Name NASDAQ
XML 10 aehr_8k_htm.xml IDEA: XBRL DOCUMENT 0001040470 2022-01-06 2022-01-06 iso4217:USD shares iso4217:USD shares 0001040470 false 8-K 2022-01-06 AEHR TEST SYSTEMS CA 000-22893 94-2424084 400 KATO TERRACE FREMONT CA 94539 510 623-9400 false false false false false Common Stock AEHR NASDAQ EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://aehr.com/role/Cover Cover Cover 1 false false All Reports Book All Reports aehr_8k.htm aehr-20220106.xsd aehr-20220106_cal.xml aehr-20220106_def.xml aehr-20220106_lab.xml aehr-20220106_pre.xml aehr_ex991.htm http://xbrl.sec.gov/dei/2020-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aehr_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "aehr-20220106_cal.xml" ] }, "definitionLink": { "local": [ "aehr-20220106_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "aehr_8k.htm" ] }, "labelLink": { "local": [ "aehr-20220106_lab.xml" ] }, "presentationLink": { "local": [ "aehr-20220106_pre.xml" ] }, "schema": { "local": [ "aehr-20220106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "aehr", "nsuri": "http://aehr.com/20220106", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_8k.htm", "contextRef": "From2022-01-06to2022-01-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://aehr.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "aehr_8k.htm", "contextRef": "From2022-01-06to2022-01-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://aehr.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001654954-22-000280-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-22-000280-xbrl.zip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